[Chemoprevention of breast cancer. Impact of a new therapeutic strategy].
Kattan
J
J
Service d'hématologie-oncologie, Hôtel-Dieu de France (HDF), Hôpital Saint-Joseph, Beyrouth, Liban. JKattan62@hotmail.com
Ghosn
M
M
D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D016588:Anticarcinogenic Agents; D004965:Estrogen Antagonists; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride